In January–July 2022, the retail sales of veterinary drugs in Russia amounted to 12.6 billion rubles (retail prices, VAT included), down 3.5% from the same period in 2021. In physical terms, the sales were 81.1 million minimum dosage units (MDU), down 19.7% from January–July 2021.

While the pharmaceutical retail quickly returned to its usual state after the March rush demand, the crisis could not go without a trace. The market is still experiencing certain problems here and there, and suppliers have begun to review the effectiveness of product portfolios. To be fair, this does not mean that portfolios have been getting smaller—quite the opposite, the portfolios of Russian companies have been actively growing.

From January to June 2022, the top Russian marketplaces sold 711.5 million rubles’ worth of veterinary drugs (retail prices, VAT included), comparable to the total sales last year (727.6 million rubles). However, the growth rates are slowing down, 84% in rubles, with Q1 contributing to the growth rates the most. In physical terms, the sales volume was 3.6 minimum dosage units (MDU), up 44% from Q1–Q2 2021.

In Q1–Q2 2022, the offline sales of veterinary drugs in the Russian retail market were 10.8 billion rubles (retail prices, VAT included), down 2% from the same period in 2021. The spring rush demand was followed by a much calmer period, when consumers were using up what they had stocked up on. Besides, the online segment has been influencing the development of the market quite a lot, while continuing to grow and attracting consumers away from the offline segment. In physical terms, the growth rate was –19.2% in minimum dosage units (MDU), with 67.1 million MDUs sold.